Douglas Genevieve, Loh Zoe, Shum Evonne S Y, Lee Sze-Ting, Waters Niamh, Hamilton Garry, Chong Geoffrey, Murphy Alexandra C, Hawkes Eliza A
Department of Clinical Haematology, Austin Health, Heidelberg, Australia.
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia.
Blood Adv. 2025 Feb 11;9(3):499-506. doi: 10.1182/bloodadvances.2024013620.
Anthracycline-mediated cardiotoxicity is a common concern after lymphoma therapy, particularly in patients with high cardiovascular risk (CVR). In noncancer populations, coronary artery calcium scoring (CACS) effectively identifies individuals who may benefit from aggressive CVR modification to lower the risk of cardiovascular events. Emerging evidence suggests that CACS can also predict cancer therapy-related cardiotoxicity, potentially identifying candidates for cardioprotective strategies. Our study aimed to evaluate whether CACS obtained from pretreatment positron emission tomography (PET)/computed tomography (CT) scans could stratify cardiac event risk in patients with lymphoma receiving anthracycline-based chemotherapy. We enrolled 358 consecutive patients with lymphoma treated between 2012 and 2022, calculating the CACS from their pretreatment PET/CT. We reviewed medical records to identify pre-existing cardiac conditions, CVR, and posttreatment cardiac events, including coronary events, heart failure (HF), and arrhythmias. Logistic and Cox regression models were used to assess associations between CVR, CACS categories (CACS = 0, CACS 1-400, CACS >400), and new cardiac events. At a median follow-up of 27 months (95% confidence interval [CI], 22.3-31.7) in patients without cardiac history, 10% experienced posttreatment cardiac events (HF, 14; arrhythmias, 9; coronary event, 1; combination, 8). Patients with a CACS >0 had more events (21 total, 20% vs 11 total, 5.4% for CACS = 0; P < .001). Elevated CACS was independently associated with HF (CACS 1-400: odds ratio [OR], 3.73; 95% CI, 1.21-11.43; P = .022; CACS >400: OR, 5.43; 95% CI, 1.47-20.03; P = .011) and any cardiac event (CACS 1-400: OR, 2.48; 95% CI, 1.02-6.04; P = .045; CACS >400: OR, 3.28; 95% CI, 0.91-10.68; P = .029). CACS may effectively stratify patients with lymphoma at risk of cardiac complications, thereby identifying a group poised to benefit from targeted preventive strategies.
蒽环类药物介导的心脏毒性是淋巴瘤治疗后常见的问题,尤其是在心血管风险(CVR)较高的患者中。在非癌症人群中,冠状动脉钙化评分(CACS)可有效识别可能从积极的CVR改善中获益以降低心血管事件风险的个体。新出现的证据表明,CACS还可预测癌症治疗相关的心脏毒性,有可能识别出适合心脏保护策略的患者。我们的研究旨在评估从治疗前正电子发射断层扫描(PET)/计算机断层扫描(CT)扫描中获得的CACS是否能对接受蒽环类药物化疗的淋巴瘤患者的心脏事件风险进行分层。我们纳入了2012年至2022年间连续治疗的358例淋巴瘤患者,根据其治疗前PET/CT计算CACS。我们查阅医疗记录以确定既往存在的心脏疾病、CVR以及治疗后心脏事件,包括冠状动脉事件、心力衰竭(HF)和心律失常。使用逻辑回归和Cox回归模型评估CVR、CACS类别(CACS = 0、CACS 1 - 400、CACS > 400)与新发心脏事件之间的关联。在无心脏病史患者的中位随访27个月(95%置信区间[CI],22.3 - 31.7)时,10%的患者发生了治疗后心脏事件(HF,14例;心律失常,9例;冠状动脉事件,1例;合并症,8例)。CACS > 0的患者发生的事件更多(共21例,20%,而CACS = 0的患者共11例,5.4%;P <.001)。CACS升高与HF(CACS 1 - 400:比值比[OR],3.73;95% CI,1.21 - 11.43;P =.022;CACS > 400:OR,5.43;95% CI,1.47 - 20.03;P =.011)和任何心脏事件(CACS 1 - 400:OR,2.48;95% CI,1.02 - 6.04;P =.045;CACS > 400:OR,3.28;95% CI,0.91 - 10.68;P =.029)独立相关。CACS可能有效地对有心脏并发症风险的淋巴瘤患者进行分层,从而识别出可能从针对性预防策略中获益的群体。